Panacea Biotec Share Price

NSE: PANACEABIO

₹ 441.20

-₹4.20 (-0.94%)

Last updated 24 Jul, 2026, 15:40 IST

Panacea Biotec Share Price Today

As of 25 Jul 2026, Panacea Biotec share price is ₹441.20. The stock opened at ₹440.00, compared to its previous close of ₹445.40. During today's trading session, Panacea Biotec share price moved in the range of ₹433.00 to ₹449.00, with an average price of ₹441.00 for the day. Looking at its last 52-week, the stock has touched a low of ₹292.40 and a high of ₹647.00. On the performance front, Panacea Biotec share price has increased by 21.18% over the last six months and is up 1.62% on a year-on-year basis.

₹433.00

0.94% down today

₹449.00

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 7.30% YoY

Latest Earning

Net Profit TrendUp by 17.89% YoY

Latest Earning

Revenue TrendUp by 1.09% QoQ

Stock Performance

OutperformingBeat Nifty by 30.31 % in last 3 month

Shareholding Pattern

DIIDII increased stake by 14.69%

Shareholding Pattern

FIIFII increased stake by 44.73%

Panacea Biotec Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹5,27,877+₹27,877 (+5.58%)

3 Year

₹16,77,567+₹11,77,567 (+235.51%)

5 Year

₹6,89,052+₹1,89,052 (+37.81%)

₹423.15₹467.65

Circuit Low

Circuit High

₹292.40₹647.00

52-Week Low

52-Week High

Circuit

₹423.15

₹467.65

52-week

₹292.40

₹647.00

Mkt Cap Cr

2,736.68

P/E

-381.88

P/B

3.28

ROE

-2.93%

D/E

0.93

ROCE

-2.42%

Div. Yield

0.00%

EPS(TTM)

-4.88

Turnover

0.73

EV/EBITDA

87.86

Net Margin

0.00%

Op. Margin

0.00%

ROA

-0.57%

Quick Ratio

0.00

Curr. Ratio

1.07

Mkt Cap Cr

2,736.68

P/E

-381.88

P/B

3.28

ROE

-2.93%

D/E

0.93

ROCE

-2.42%

Div. Yield

0.00%

EPS(TTM)

-4.88

Turnover

0.73

EV/EBITDA

87.86

Net Margin

0.00%

Op. Margin

0.00%

ROA

-0.57%

Quick Ratio

0.00

Curr. Ratio

1.07

Based on fundamentals, this stock's

Performance

Very Poor

Panacea Biotec has not beaten FD return of 7%

Valuation

Overvalued

Panacea Biotec appears overvalued compared to its peers

Earnings

Good

Panacea Biotec revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,68,842.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	97,364.90	30.58	2.56	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.45	16.70%	10.19	0.20%	0.97	13.72

Panacea Biotec Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹559.09	₹559.17	₹459.95	₹661.23
Other Income	₹20.66	₹25.80	₹51.66	₹10.97
Total Revenue	₹579.75	₹584.96	₹511.61	₹672.20
Total Expenses	₹623.70	₹619.52	₹601.47	₹899.05
Profit Before Tax	-₹7.95	₹1.48	₹12.81	₹1,449.36
Tax	₹0.77	₹2.98	₹46.55	₹371.02
Profit After Tax	-₹8.72	-₹1.51	-₹33.75	₹1,078.33
EPS - Basic	-₹1.37	-₹0.19	-₹5.43	₹176.05
EPS - Diluted	-₹1.37	-₹0.19	-₹5.43	₹176.05

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	-₹7.95	₹1.48	₹12.81	₹1,449.36
Income before WC changes	-₹17.82	-₹7.28	-₹83.06	-₹5.61
Change in Assets	-₹101.58	-₹0.85	-₹13.27	-₹73.14
Change in Liabilities	₹93.00	₹10.54	-₹323.65	₹374.00
Change in WC	-₹8.58	₹9.69	-₹336.91	₹300.86
Cash flow from Operations	-₹27.37	-₹0.10	-₹422.45	-₹108.45
Cash flow from Investing	₹64.98	₹10.23	₹430.33	₹1,282.57
Cash flow from Financing	-₹2.66	-₹2.81	-₹18.37	-₹1,175.85
Total Cash Flow	₹34.95	₹7.32	-₹10.49	-₹1.73
Cash (Start of the year)	₹47.17	₹39.85	₹50.35	₹52.08
Cash (End of the year)	₹82.13	₹47.17	₹39.85	₹50.34

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹744.57	₹755.49	₹708.85	₹808.31
Current Assets	₹545.18	₹485.18	₹562.32	₹950.56
Total Assets	₹1,289.75	₹1,240.67	₹1,271.17	₹1,758.87
Current Liabilities	₹366.99	₹308.83	₹329.73	₹776.37
Net Current Asset	₹178.19	₹176.35	₹232.59	₹174.19
Non-Current Liabilities	₹92.14	₹93.61	₹101.32	₹108.85
Equity Capital	₹830.62	₹838.23	₹840.11	₹873.66
Total Equity & Liabilities	₹1,289.75	₹1,240.67	₹1,271.17	₹1,758.87

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹309.86	₹359.60	₹257.07	₹235.50
Other Income	₹16.62	₹24.91	₹34.44	₹12.57
Total Revenue	₹326.47	₹384.51	₹291.50	₹248.07
Total Expenses	₹352.53	₹380.31	₹354.25	₹341.65
Profit Before Tax	-₹26.06	₹4.21	-₹62.75	-₹93.58
Tax	-₹10.83	₹0.66	₹24.79	₹0.00
Profit After Tax	-₹15.23	₹3.55	-₹87.54	-₹93.58
EPS - Basic	-₹2.49	₹0.58	-₹14.29	-₹15.28
EPS - Diluted	-₹2.49	₹0.58	-₹14.29	-₹15.28

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	-₹26.06	₹4.21	-₹62.75	-₹93.58
Income before WC changes	₹3.87	₹30.95	-₹52.32	-₹57.60
Change in Assets	-₹50.40	₹0.78	₹5.19	-₹38.97
Change in Liabilities	₹51.58	₹3.22	₹37.48	₹44.70
Change in WC	₹1.18	₹4.00	₹42.67	₹5.73
Cash flow from Operations	₹3.94	₹33.07	-₹10.74	-₹52.69
Cash flow from Investing	-₹60.60	-₹46.80	₹2.41	₹39.54
Cash flow from Financing	₹90.07	₹12.82	₹9.01	₹9.83
Total Cash Flow	₹33.41	-₹0.91	₹0.67	-₹3.32
Cash (Start of the year)	₹5.09	₹6.01	₹5.33	₹8.66
Cash (End of the year)	₹38.50	₹5.09	₹6.01	₹5.33

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹575.74	₹570.30	₹524.77	₹513.01
Current Assets	₹293.73	₹183.49	₹199.13	₹248.83
Total Assets	₹869.47	₹753.79	₹723.90	₹761.83
Current Liabilities	₹351.40	₹249.14	₹250.85	₹246.76
Net Current Asset	-₹57.67	-₹65.65	-₹51.72	₹2.07
Non-Current Liabilities	₹204.10	₹175.51	₹147.40	₹99.98
Equity Capital	₹313.97	₹329.14	₹325.65	₹415.09
Total Equity & Liabilities	₹869.47	₹753.79	₹723.90	₹761.83

* All values are in INR Crore

Qty

Bid

497

441.2

Ask

Qty

Bid Total: 497

Ask Total: 0

Buy orders: 100%

Sell orders: 0%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

32.27

Neutral

ATR (14)

29.15

Neutral

STOCH(9,6)

2.52

Bullish

STOCH RSI (14)

Bullish

ADX(9)

38.6

Bearish

UO(9)

29.56

Bullish

ROC(12)

-17.27

Bearish

WillR(14)

-97.48

Bullish

Period

Simple value

Exponential vaue

499.81

486.87

10D

522.79

509.35

20D

535.15

520.98

50D

500.58

496.27

100D

421.73

454.81

About Panacea Biotec

ISIN

INE922B01023

Sector Market Cap

₹ 2,736.68 Cr

Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.

Panacea Biotec Financial Highlights

Revenue: Panacea Biotec reported revenue of ₹656.67 crore in FY26 vs ₹579.75 crore in FY25. It showed an increase of 13.27% on a yearly basis.
Operating Profit: Panacea Biotec reported an operating loss of ₹7.37 crore in FY26 vs ₹7.95 crore in FY25. It showed an increase of 7.30% on a year-on-year basis.
Net Profit: Panacea Biotec reported a net loss of ₹7.16 crore in FY26 vs ₹8.72 crore in FY25. It showed an increase of 17.89% on a yearly basis.

Panacea Biotec Quarterly Result Highlights

Panacea Biotec reported revenue of ₹169.30 crore in Mar 2026, compared with ₹167.47 crore in Dec 2025, representing an increase of 1.09% on a quarter-on-quarter (QoQ) basis.
Panacea Biotec reported an operating loss of ₹1.25 crore in Mar 2026, compared with ₹6.49 crore in Dec 2025, representing a decrease of 119.26% on a quarter-on-quarter (QoQ) basis.
Panacea Biotec reported a loss of ₹1.00 crore in Mar 2026, compared with ₹3.89 crore in Dec 2025, reflecting a decrease of 125.71% on a QoQ basis.
The earnings per share (EPS) of Panacea Biotec stood at ₹1.37 during Mar 2026.